Collectively, the findings of this study involving a gene-modification approach indicate that ERO1α is a major proliferation-enhancing factor in cancer cells and could be used as both a diagnostic biomarker of cancer exacerbation and a therapeutic target. This evidence concerns the gene ERO1A and cancer.